Clinical Trial Update: Safety and Efficacy of Expanded, Universal Donor Natural Killer Cells for Relapsed/Refractory AML [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on the safety and efficacy of expanded, universal donor natural killer cells for relapsed/refractory acute myeloid leukemia; the Phase 1/P…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Expanded, universal donor natural killer cells (natural killer cells)

Snippet

Sponsor: Nationwide Children's Hospital | Conditions: Acute Myeloid Leukemia | Phase 1, Phase 2 | Status: RECRUITING